The Money of Invention- Experimenting with The Biotech Risk Capital Model

THE MONEY OF INVENTION-Experimenting with The Biotech Risk Capital Model

EVENT SUMMARY

Thursday | May 3, 2012

The Biotech and Pharma industry is rapidly changing in an effort to meet the current
demands from the market, regulators, investors and economic pressures.

Please join us for an interactive discussion as we draw on our panel's experience
and look at case studies of successes and failures in biopharma investments and
identify the challenges, priorities and the role of strategic partners and much more.

5:30pm — 9:00pm

Non-Service Provider: $35.00*
Service Provider: $50.00

Please register at:

http://themoneyofinvention-eorg.eventbrite.com/

*Includes Biotech, Pharma, and Academia Professionals

MODERATOR
BRUCE BOOTH
Partner, Life Sciences Group, Atlas Venture

PANEL
DAPHNE ZOHAR
Founder, Managing Partner, PureTech Ventures

JASON RHODES
Chief Business Officer, Epizyme, Inc.

VIN MILES
Venture Partner, Abingworth LLP

BARRETT BREADY
Chief Executive Officer, Nabsys Inc.

Event Sponsor:
Finnegan

With more than 375 intellectual property lawyers, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. For more information, please visit www.finnegan.com

CORPORATE SPONSORS:
DLA Piper, LLP The Richmond Group